Cargando…
Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy
Cancer immunotherapy has made rapid progress over the past decade leading to high enthusiasm and interest worldwide. Codelivery of immunomodulators with chemotherapeutic agents and radioisotopes has been shown to elicit a strong and sustained immune response in animal models. Despite showing promisi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532032/ https://www.ncbi.nlm.nih.gov/pubmed/33082845 http://dx.doi.org/10.3332/ecancer.2020.1095 |
_version_ | 1783589838909341696 |
---|---|
author | Selvaraja, Vinodh Kumar Gudipudi, Deleep Kumar |
author_facet | Selvaraja, Vinodh Kumar Gudipudi, Deleep Kumar |
author_sort | Selvaraja, Vinodh Kumar |
collection | PubMed |
description | Cancer immunotherapy has made rapid progress over the past decade leading to high enthusiasm and interest worldwide. Codelivery of immunomodulators with chemotherapeutic agents and radioisotopes has been shown to elicit a strong and sustained immune response in animal models. Despite showing promising results in metastatic and recurrent cancers, the utilisation of immunotherapy in clinical settings has been limited owing to uncertainties in elicited immune response and occurrence of immune-related adverse events. These uncertainties can be overcome with the help of nanoparticles possessing unique properties for the effective delivery of targeted agents to specific sites. Nanoparticles play a crucial role in the effective delivery of cancer antigens and adjuvants, modulation of tumour microenvironment, production of long-term immune response and development of cancer vaccines. Here, we provide a comprehensive summary of nanotechnology-based cancer immunotherapy and radiotherapy including basics of nanotechnology, properties of nanoparticles and various methods of employing nanoparticles in cancer treatment. Thus, nanotechnology is anticipated to overcome the limitations of existing cancer immunotherapy and to effectively combine various cancer treatment modalities. |
format | Online Article Text |
id | pubmed-7532032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-75320322020-10-19 Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy Selvaraja, Vinodh Kumar Gudipudi, Deleep Kumar Ecancermedicalscience Review Cancer immunotherapy has made rapid progress over the past decade leading to high enthusiasm and interest worldwide. Codelivery of immunomodulators with chemotherapeutic agents and radioisotopes has been shown to elicit a strong and sustained immune response in animal models. Despite showing promising results in metastatic and recurrent cancers, the utilisation of immunotherapy in clinical settings has been limited owing to uncertainties in elicited immune response and occurrence of immune-related adverse events. These uncertainties can be overcome with the help of nanoparticles possessing unique properties for the effective delivery of targeted agents to specific sites. Nanoparticles play a crucial role in the effective delivery of cancer antigens and adjuvants, modulation of tumour microenvironment, production of long-term immune response and development of cancer vaccines. Here, we provide a comprehensive summary of nanotechnology-based cancer immunotherapy and radiotherapy including basics of nanotechnology, properties of nanoparticles and various methods of employing nanoparticles in cancer treatment. Thus, nanotechnology is anticipated to overcome the limitations of existing cancer immunotherapy and to effectively combine various cancer treatment modalities. Cancer Intelligence 2020-09-01 /pmc/articles/PMC7532032/ /pubmed/33082845 http://dx.doi.org/10.3332/ecancer.2020.1095 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Selvaraja, Vinodh Kumar Gudipudi, Deleep Kumar Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy |
title | Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy |
title_full | Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy |
title_fullStr | Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy |
title_full_unstemmed | Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy |
title_short | Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy |
title_sort | fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532032/ https://www.ncbi.nlm.nih.gov/pubmed/33082845 http://dx.doi.org/10.3332/ecancer.2020.1095 |
work_keys_str_mv | AT selvarajavinodhkumar fundamentalstoclinicalapplicationofnanoparticlesincancerimmunotherapyandradiotherapy AT gudipudideleepkumar fundamentalstoclinicalapplicationofnanoparticlesincancerimmunotherapyandradiotherapy |